CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
Patent damages jury verdicts aren't always end of the story
It has been over three years since Intel Corporation was ordered by a federal jury to pay VLSI Technology LLC over $2 billion in damages. During that time, the...